Tvardi Therapeutics Expands At-The-Market Equity Program
at www.tipranks.com (Fri, 17-Jul 5:32 PM)
Tvardi’s TTI-109 Phase 1 Data Shows Up to 60% Immune Cell Reduction and Superior Tolerability Over TTI-101
Market Chameleon (Wed, 8-Jul 11:08 AM)
TTI-109 Phase 1 Results Show Meaningful Reductions in STAT3-Driven Immune Cells—Path Cleared for Dermatologic and GI Trials Pending Funding
Market Chameleon (Tue, 7-Jul 10:29 AM)
